XML 44 R34.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Discontinued Operations (Tables)
 3 Months Ended
Mar. 30, 2024
Discontinued Operations and Disposal Groups [Abstract]  
Schedule of Balance Sheet and Statement of Operation
The following table summarizes the major income and expense line items of these discontinued operations, as reported in the consolidated statements of operations for the three months ended April 1, 2023:
Three Months Ended
March 30, 2024April 1, 2023
Selling, general and administrative expense$— $1,728 
Research and development expense— 396 
Change in fair value of contingent consideration(a)
— 1,710 
Depreciation and amortization(a)
— 4,264 
Impairments of assets— — 
Operating loss from discontinued operations— 8,098 
Interest expense, net— 4,889 
Other (income) expense(b)
— 61,442 
Other (income) expense— 66,331 
Loss before income taxes— (74,429)
Income tax benefit, net— — 
Net loss from discontinued operations— (74,429)
Loss attributable to noncontrolling interest -
    discontinued operations		— 14,937 
Net loss attributable to Bioventus Inc. -
    discontinued operations		$— $(59,492)
(a)Depreciation and amortization and the change in fair value of contingent consideration represents the significant operating non-cash items of discontinued operations.
(b)Other expense includes the $60,639 loss on deconsolidation, of which $10,150 was attributable to non-refundable payments. Total investing cash outflows included these non-refundable payments and $1,356 cash on hand at disposal.